Article · 2021
Editor-in-Chief
Marek Malecki
President, San Francisco, USA
About
As published by the journal they serve.
Marek Malecki MD PhD developed a novel cancer suicide gene therapy. He initially developed it for ovarian cancers as the means of protecting women’s fertility and eliminating risks of genetic diseases in the offspring. It is based upon the novel biotechnology, which he invented and patented. He is currently a Visiting Professor at the UW, Madison and PBMEF, San Francisco. He earned MD degree at the Medical Academy, Poznan followed by Residency/Fellowship in Molecular Medicine in Rigshospitalet, Copenhagen. He earned PhD at the Polish Academy of Sciences, Warsaw followed by the EMBO and AAS postdoctoral fellowships in molecular biology at the Austrian Academy of Sciences, Salzburg, ETH, Zurich, Utrecht University, Utrecht, Cancer Center, Vienna, Cancer Center, Amsterdam, Biozentrum, Basel.
Research interests
Journals they serve
The seats these journals name them in.
- Journal of Genetic Syndromes & Gene TherapyEditor-in-Chief
Articles we hold
Articles in the journals they serve whose byline carries this name.
Article · 2021
Cancer Gene
Article · 2015
Novel Mutation-Deletion in the PHOX2B Gene of the Patient Diagnosed with Neuroblastoma, Hirschsprungs Disease, and Congenital Central Hypoventilation Syndrome (NB-HSCR- CCHS) Cluster
Article · 2013
Suicide Gene Therapy for Cancer - Current Strategies
Article · 2013
Eradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1 , DNASE1L3 , DNASE2 , and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer?
Article · 2012
Frontiers in Suicide Gene Therapy of Cancer
Article · 2012
Cancer Suicide Gene Therapy
Article · 2012
Cancer suicide gene therapy: Apoptosis of the ovarian cancer cells induced by EGFRvIII targeted delivery and cell nucleus targeted expression of the DNA-ase transgenes
This page holds what the journals publish about this profile: no contact details, and nothing gathered from anywhere else. Ask us to correct or remove this profile.
